Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Content validity evidence for a simulation-based test of handheld otoscopy skills

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. European white paper: oropharyngeal dysphagia in head and neck cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Salivary gland carcinoma in Denmark: a national update and follow-up on incidence, histology, and outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Developing a national e-learning course in otorhinolaryngology: the Danish experience

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Ultra-high-fidelity virtual reality mastoidectomy simulation training: a randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Surgeons' experience of venous risk with CPA surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The natural history of Vestibular Schwannoma growth - prospective 40-year data from an unselected national cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Objective Vestibular Test Battery and Patient Reported Outcomes in Cochlear Implant Recipients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

The hallmark of neurofibromatosis type 2 (NF2) is bilateral vestibular schwannomas (VS) and severe hearing loss is common in NF2 patients. Vascular endothelial growth factor (VEGF) expression level in NF2 correlates with tumour growth rate and bevacizumab, a VEGF-binding antibody, has previously been shown to induce tumour shrinkage and improve hearing. We retrospectively reviewed the effect of bevacizumab on hearing and VS tumour size in 12 consecutive NF2 patients. Bevacizumab 10 mg/kg was administered intravenously every second week for 6 months; hereafter, bevacizumab 15 mg/kg was administered every third week. Patients were evaluated with repeated audiometries, MR scans and clinical evaluations. Radiological response was defined as a 20 % or greater reduction in VS volume. A total of 398 treatments (median 36) were administered and the median duration on therapy was 22 months (range 7-34). We observed a radiological response (≥20 % tumour shrinkage) in seven out of 18 tumours (39 %) in six out of 12 patients (50 %). Sustained radiological responses were maintained in six tumours (33 %) for more than 2 months. Three patients had objectively improved hearing and five patients reported subjective benefit in neurological symptoms, including improved hearing. Toxicity was in general manageable; however, one patient died from cerebral haemorrhage which was possibly related to therapy. In conclusion, bevacizumab improved hearing and reduced the size of VS in some patients with progressive NF2 which corroborates previous findings; however, the risk of severe side effects should be carefully considered and discussed with the patients prior to treatment.

OriginalsprogEngelsk
TidsskriftEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
Vol/bind272
Udgave nummer12
Sider (fra-til)3627-33
ISSN0937-4477
DOI
StatusUdgivet - 2015

ID: 44956003